Manufacturing Misery in Vaccines - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Manufacturing Misery in Vaccines
Vaccine manufacturing was predicted in 2008 to be on the cusp of a golden era, but instead the industry has experienced cost pressures, high-profile liability cases and production setbacks.


Pharmaceutical Technology Europe


References

1. L. Galambos, What are the Prospects for a New Golden Era in Vaccines? (UK Vaccines Group, UK, 2008).

2. Pharmaletter website, "Novartis' flu vaccines suspended in several countries on suspected quality issues", http://www.thepharmaletter.com/, accessed 12 Dec., 2012.

3. Fiercepharma website, "Italy bans Novartis vaccines even after company assures their safety", http://www.fiercepharma.com/, accessed 12 Dec., 2012.

4. Reuters website, "France halts sale of Novartis flu vaccine", http://uk.reuters.com/, accessed 12 Dec., 2012.

5. Deutsche Welle website, "Germany moves to cut off vaccine shortage", http://www.dw.de/, accessed 12 Dec., 2012.

6. The Globe and Mail website, "Canada suspends distribution of Novartis flu shots", http://www.theglobeandmail.com/, accessed 12 Dec., 2012.

7. Fiercepharma website, "Novartis plant delay, vaccine woes steal spotlight", http://www.fiercepharma.com/, accessed 12 Dec., 2012.

8. Health Canada website, "Health Canada Endorsed Important Safety Information on Infanrix Hexa", http://www.hc-sc.gc.ca/, accessed 12 Dec., 2012.

9. In-pharmatechnologist website, "GSK pulls vaccine batch in Canada over contamination concerns", http://www.in-pharmatechnologist.com/, accessed 12 Dec., 2012.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology Europe,
Click here